Aza cyclohexapeptide compounds

• US 5,514,650 A
• Filed: 08/29/1994
• Issued: 05/07/1996
• Est. Priority Date: 03/16/1993
• Status: Expired due to Term

• Current Assignee: Merck Sharp & Dohme Corporation (Merck & Co., Inc.)
• Original Assignee: Merck & Co., Inc.
• Inventors: Balkovec, James M., Bouffard, Frances A., Black, Regina M.
• Primary Examiner(s): Chan, Christina Y.
• Assistant Examiner(s): Wessendorf, T. D.
• Application Number:
  US08/298,479
• Time in Patent Office: 617 Days
• Field of Search: 514/11,9,2, 530/317, 930/270, 930/DIG. 548, 930/DIG. 546
• US Class Current: 514/3.3
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 33/08 for Pneumocystis carinii
• CPC Class Codes: C07K 7/56 the cyclisation not occurring through 2,4-diamino-butanoic acid
• CPC Class Codes: Y10S 930/27 Cyclic peptide or cyclic protein

Abstract

Ceretain aza cyclohexapeptide compounds have been found to have superior antibiotic properties. Novel processes for their preparation are also described.

Claims

1. An antimicrobial composition comprising a compound selected from the group consisting of ##STR19## or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier.

2. A method for controlling mycotic infections comprising administering to a mammalian subject in need of treatment, an antimycotic amount of a compound selected from the group consisting of ##STR20## or a pharmaceutically acceptable salt thereof.

3. A method for controlling Pneumocystis pneumonia in immune-compromised patients comprising administering a therapeutically effective amount of a compound selected from the group consisting of ##STR21## or a pharmaceutically acceptable salt thereof.